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LO-C.01 ABSORBABLE BIOPROSTHESIS
FOR THE TREATMENT OF BILE DUCT
INJURY IN AN EXPERIMENTAL MODEL
E. E. Montalvo Javé1,5, A. R. Jaime Limon1, M. J. Kim
Koh1, M. A. García Pineda1,5, B. León Mancilla1, F. Rojas
Mendoza 2, J. Tapia Jurado1, C. Montalvo Arenas3 and
J. A. Saavedra 4
1Department of Surgery, School of Medicine, Universidad
Nacional Autónoma de México (UNAM), MEXICO CITY,
MEXICO; 2Department Of Gastroenterology, Medica Sur
Clinic Foundation, MEXICO CITY, MEXICO; 3Department
Of Cellular And Molecular Biology, School Of Medicine,
UNAM, MEXICO CITY, MEXICO; 4Department Of
Pathology, Medica Sur Clinic Foundation, MEXICO CITY,
MEXICO; 5Department Of Surgery, Hospital General De
México, MEXICO CITY, MEXICO
Biodegradable stent implants are an alternative replacement
of the bile duct due to benign stenosis, bile duct injury or
cancer. We employed an acellular bone based bioprosthesis
(10% water, 65% collagen, 25% hydroxyapatite) as an alter-
nate treatment for biliary injury. Eight Landrace pigs under-
went an initial laparotomy in which 3 cm of the common bile
duct was excised. An end to end anastomosis (bile duct-
prosthesis-bile duct) with the liquid collagen coated and
hydrogen peroxide gas plasma sterilized bioprosthesis was
performed. Every pair of pigs underwent a 1, 6, 12, 18-month
follow-up, with liver function test, cholangiography,
cholangioresonance, cholangioscopic procedure with Spy-
glass, Cytokeratin (CK-7, CK-19) immunohistochemistry,
and H-E staining for microscopic evaluation. No mortality or
infectious complications were observed. All gained weight.
None showed acolia or jaundice, nor increased hepatobiliary
enzymes preoperatively or at 7, 30, 60, 90 or 180 days.
Cholangioresonance showed adequate permeability and no
stenosis, moderate dilatation of extra-intrahepatic ducts were
found in an 18-month follow-up model. Cholangioscopy
with Spyglass showed the bioprosthesis insertion in place,
without stenosis. No necrosis, stricture or bile leakage was
found on the exploratory laparotomy. Biopsies were obtained
from the bifurcation of the bile duct to the descending duo-
denum, including the graft site. Microscopy at 1-month post-
implantation showed a rich deposit of collagen fibers with
inflammatory cellular infiltrate. At the 3-month the graft site
developed a columnar epithelium similar to the original,
CK-7 and CK-19 positive. This collagen based bioprosthesis
has potential for its application as a novel treatment for
biliary injury and stenosis.
LO-C.02 NATIONAL VIEW ON BILIARY
CANCER: RISING RESECTIONS AND
CONSIDERABLE COMPLICATIONS
C. J. Yang1, L. A. Bliss1, W. B. Al-Refaie2, A. R. Evenson1,
K. Khwaja1, S. C. Ng1 and J. F. Tseng1
1Beth Israel Deaconess Medical Center, Boston, MA;
2MedStar Georgetown University Hospital, Washington,
DC
Background: Resection remains the mainstay of curative
treatment for biliary tract neoplasms. Literature suggests
a minority of eligible patients undergo resection. Aim of this
study was to describe current trends in hepatopan-
creaticobiliary resections and to delineate complication rates.
Methods: Retrospective review of U.S. Nationwide Inpa-
tient Sample 2004–2011 for biliary tract cancer. Procedures:
Hepatectomy, lobectomy, cholecystectomy, ablation of liver
lesion, bile duct resection, biliary-enteric anastomosis,
pancreaticoduodenectomy. Categorical variables analyzed by
χ2, trend analyses by Cochran-Armitage, adjusted predictors
of outcomes by multivariable logistic regression.
Results: 238,968 patient-discharges occurred. 40,414
(16.9%) underwent resection. Majority of resections were
performed at teaching hospitals (87.3%) and on elective
admissions (82.8%). Proportion of patients resected and
proportion at teaching hospitals increased over time
(p < 0.0001). Mortality remained stable over time 4.2% (2.9–
4.9%). There was a statistically significant increase in com-
plications over time (p < 0.0001). Complication rates were
not affected by teaching status or by annual HPB case-
volume of hospital after adjusting for confounding. Risk
factors for complication: emergency admission (OR 1.75,
95% CI 1.49–2.05), Medicare (vs private insurance; OR
1.18, 95% CI 1.02–1.38), male (OR 1.42, 95% CI 1.25–
1.61), increasing comorbidities, and age ≥50 (OR 1.54, 95%
CI 1.28–1.85).
Conclusion: An increasing proportion, yet still a minority,
of biliary tract cancers are being resected in the US. There
has been a shift towards teaching hospitals, high volume
centers, and elective admissions. Despite this favorable trend,
complication rates are substantial. To maximize the benefit of
hepatopancreaticobiliary resections to this small cohort of
patients, future investigations should target complication
reduction interventions.
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LO-C.03 IS LOCAL RESECTION
ADEQUATE FOR T1 STAGE AMPULLARY
CANCER?
A. Amini, J. Miura, T. Jayakrishnan, F. Johnston,
S. Tsai, K. Christians, C. Gamblin and K. Turaga
Medical College Of Wisconsin, Milwaukee, WISCONSIN
Introduction: Concerns for morbidity of pancreaticoduo-
denectomy (PD) has led to practitioners adopting endoscopic
resection or ampullectomy without lymphadenectomy in the
treatment of T1 ampullary cancer. We hypothesized that sur-
vival for patients undergoing local resection of ampullary
cancer was inferior to those undergoing PD.
Methods: All patients with ampullary cancer reported in the
Surveillance, Epidemiology, and End Results database
between 2004 and 2010 were collected. Demographic fea-
tures, adjuvant radiation and 5-year survival rates according
to nodal disease and histologic type were compared.
Results: There were 1,916 cases of ampullary cancer and
421 (22%) had T1 disease. Among those with T1 disease,
217 (51%) received endoscopic treatment only, 21 (5%)
underwent ampullectomy alone, 20 (5%) underwent
ampullectomy with regional lymphadenectomy, and 163
(39%) underwent PD. For patients with complete nodal
staging (PD), 23% had metastatic disease in the nodes. Grade
was significantly associated with node positivity with 10%
positivity in well-differentiated (n = 61), 12% in moderately-
differentiated (n = 163), and 27% in poorly-differentiated
tumors (n = 85, P = 0.007). After adjusting for demographic
characteristics, node positivity was significantly associated
with a worse survival (HR 2.2 (95% CI 1.3–3.8, p = 0.003))
in multivariate models. Survival was improved with either an
ampullectomy with regional lymphadenectomy (HR 0.16
(95% CI 0.08-0.03, p < 0.001)) or a PD (HR 0.26 (95% CI
0.15–0.44, p < 0.001)).
Conclusion: Patients with early stage ampullary cancer
have a high risk for nodal metastases especially if they are
higher grade lesions. Nodal clearance with a regional
lymphadenectomy or a PD is essential to ensure long term
survival for these patients.
LO-C.04 MODEL TO PREDICT SURVIVAL
AFTER SURGICAL RESECTION
OF INTRAHEPATIC
CHOLANGIOCARCINOMA:
THE MAYO EXPERIENCE
S. M. Ali1, C. J. Clark1, T. Mounajjed3, T. Wu3,
W. Harmsen2, K. M. Reid-Lombardo1, M. L. Kendrick1,
M. B. Farnell1, D. M. Nagorney1 and F. Que1
1Division Of Gastroenterologic And General Surgery,
Rochester, MN; 2Division Of Biostatistics, Rochester, MN;
3Division Of Anatomic Pathology, Rochester, MN
Background: The AJCC 7th edition has recently been vali-
dated and shown to accurately predict survival of patients
with intrahepatic cholangiocarcinoma (ICC). We attempted
to investigate the validity of recent findings.
Methods: A single center retrospective cohort study; with
histo-pathological restaging of all consecutive ICC patients
who underwent primary surgical resection between 1997 and
2011. Patients with metastatic disease, palliative operations
or evidence of hepatocellular/cholangiocarcinoma variant on
microscopic examination were excluded. Overall survival
was compared using Kaplan-Meier estimates and log-rank
tests.
Results: A total of 151 patients (54% females) with median
follow up of 4.5 years met our inclusion criteria. The mean
age and mean BMI of the cohort was 58.7 ± 12.1 years and
28.3 ± 5.6 kg/cm2 respectively. AJCC was [stage I, 44(29%),
Stage II, 44(29%), Stage III, and Stage III/IVa 63(42%)].
Type of tumor growth was periductal in 36 (25%) patients
and mass forming in 105 (75%) patients. Nine(6%) patients
had cirrhosis, 19(12%) had steatohepatitis and 68 (45%) had
necrosis. Tumor grade was low in 75 (49%) and high in
76(51%) patients. Resection margin was <1 mm in 35 (25%),
2–9 mm in 63(45%) and >10 mm in 41(30%) patients. Major
liver resection (>3 segments) was performed in 64 (42%)
patients. Survival analysis showed statistically significant
results for cirrhosis (p < 0.01), resection margin (p < 0.01),
grade (p < 0.01) and AJCC staging (p = 0.04).
Conclusions: Our analysis shows that in addition to AJCC
criteria; inclusion of grade, tumor growth type, extent of
resection margin and cirrhosis offers a more accurate model
for survival in our cohort.
LO-C.05 ECONOMIC ANALYSIS OF
NEAR INFRARED NAVIGATING
SURGERY IN CHOLECYSTECTOMIES IN
CLEVELAND CLINIC FLORIDA
F. Dip, M. Roy, A. Rosales-Velderrain, C. Simpfendorfer,
E. Lo-Menzo, R. Rosenthal and S. Szomstein
Cleveland Clinic Florida, Weston, FLORIDA
Introduction: Fluorescent cholangiography (FC) is a novel
intraoperative procedure involving infrared visualization of
the biliary structures. We evaluated the costs and effective-
ness of routinely implemented FC and intraoperative
cholangiogram (IOC) during laparoscopic cholecystectomy
(LC).
Material and Methods: All patients enrolled in an IRB
approved prospective study comparing LC with FC and IOC
between February and June 2013 were reviewed. The pro-
cedure time, procedure cost and effectiveness of the two
methods were analyzed and compared.
Results: A total of 43 patients (21 males and 22 females)
were analyzed. The mean age was 49.53 ± 14.35 years and
mean body mass index (BMI) was 28.35 ± 8 kg/m2. The
overall mean operative time was 64.95 ± 17.43 minutes. FC
was faster than IOC (0.71 ± 0.26 mins vs. 7.15 ± 3.76 mins;
p < 0.0001). FC was successfully performed in 43 out of 43
cases (100%) and IOC in 40 out of 43 cases (93.02%). FC
was less expensive than IOC (14.10 ± 4.31 vs. 778.43 ± 0.40
dollars; p < 0.0001). All surgeons found the routine use of FC
useful.
Conclusion: In our study FC was effective in delineating
important anatomic structures during LC. It was cheaper than
IOC.
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LO-C.06 COMPARISON OF LONG TERM
SURVIVAL BETWEEN LIVER
TRANSPLANTATION AND RESECTION
IN PATIENTS WITH STAGE I AND II
CHOLANGIOCARCINOMA – A
NATIONAL RETROSPECTIVE ANALYSIS
R. M. Seshadri, D. J. Niemeyer, R. Z. Swan, D. Sindram,
J. B. Martinie, M. Russo and D. A. Iannitti
Carolinas Medical Center, Charlotte, NC
Introduction: Optimal surgical and oncologic treatment for
patients with early stage hepatocellular carcinoma is consid-
ered to be liver transplantation. It is unknown if a similar
survival benefit exists for cholangiocarcinoma (CCA). We
aimed to investigate the comparative survival of early stage
cholangiocarcinoma treated with resection, locoregional
therapy or transplantation.
Methods: Stage I and II CCA patients (from 1998–2006)
were identified from the National Cancer Database (a joint
venture of the Commission on Cancer and the American
Cancer Society) and survival analysis was calculated using
Kaplan Meier Curves and Log Rank tests.
Results: 837(452 M /385 F) patients with stage I or II CCA
(out of 7581 CCA pts) met criteria for the study. 81 patients
(66 M, 15 F) had LT, 376 patients (164 M, 212 F) had LR
and 38 had LRTX (22 M, 17 F). The mean age of LR, LT,
LRTX groups was 54, 64 and 65 respectively. Median sur-
vival for patients who underwent LT was 89.9 months, LR
was 49 months and LRTX was 19.6 months.
Conclusion: There was no statistical difference between
patients undergoing a liver transplant or a resection
(p = 0.07). The survival curves suggest that liver resection
offers a survival benefit after 3 years compared to transplant.
The locoregional therapy group had the lowest survival but
this may be due to patient or tumor characteristics which
could not be validated from the database.
LO-C.07 HEPATIC ARTERIAL FLOW
PREDICTS BILIARY COMPLICATIONS
AND SURVIVAL IN LIVER TRANSPLANT
RECIPIENTS
P. T. Kim, G. Saracino, L. Jennings, M. Ramsay,
G. J. McKenna, G. Testa, N. Onaca, T. L. Anthony,
R. Ruiz, M. Levy, R. Goldstein and G. Klintmalm
Baylor University Medical Center, Dallas, TX
Introduction: Adequate hepatic arterial (HA) flow to the
bile duct is essential for its viability in liver transplantation.
This study was conducted to determine the relationship
between directly measured hepatic arterial (HA) flow and
biliary complications and survival after deceased donor liver
transplantation.
Methods: A retrospective review of HA and portal vein
flows from 2684 liver transplant recipients over a 25-year
period was performed from a prospectively maintained
database. Rates of biliary complications (biliary leaks,
anastomotic and non anastomotic strictures) and survival
were compared between two groups: patients with HA flow
per body weight ratio of <5 ml/min/kg (N = 884), (Group 1)
and >5 ml/min/kg (N = 1800), (Group 2).
Results: Patients in Group 1 had higher body weight (93 vs.
77 kg, P < 0.0001), higher MELD scores (17 vs. 16,
P = 0.0002), lower HA flow (352 vs. 617 ml/min,
P < 0.0001), and higher portal venous (PV) flow 2206 vs.
2143 ml/min, P = 0.0452). There was no difference in cumu-
lative hepatic arterial complications between the groups
(13.9 vs. 12.2%, P = 0.2191). Pattients in Group 1 had higher
rates of biliary complications at 2 months, 6 months and 12
months (19.8%, 28.2% and 31.9% vs. 14.8%, 22.4% and
25.8%, respectively, P < 0.001) and lower graft and overall
survival at 1 year, 2 years and 5 years (graft: 79.4%, 73.4%,
and 63.5% vs. 85.8%, 81.1% and 71.5%, P = 0.001; overall
84.3%, 79%, 68.7% vs. 89%, 84.3%, and 75.2%, P < 0.001).
Conclusion: Hepatic arterial flows per weight ratio of
<5 ml/min/kg predicts biliary complications and is associ-
ated with lower graft and patient survival.
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LO-C.08 LIVER TRANSPLANTATION IS A
HIGHLY EFFECTIVE TREATMENT FOR
MANAGEMENT OF HEPATOCELLULAR
CARCINOMA, EVEN FOR HIGHLY
SELECTED ADVANCED STAGE
PATIENTS
M. Doyle, N. Vachharajani, K. Fowler, K. Korenblat,
J. Lowell, S. Shenoy, J. Crippin, Y. Lin, J. Wellen, N. Saad
and W. Chapman
Washington University School Of Medicine, St. Louis, MO
Introduction: Optimal management of HCC remains con-
troversial, with a high recurrence rate in patients undergoing
hepatic resection. While results for orthotopic liver trans-
plantation (OLT) have been favorable within Milan, concerns
about recurrence have limited this therapy in patients beyond
Milan. Since 2000, we have used a strategy of downstaging
with a 4–6 month period of observation prior to OLT.
Method: We reviewed our experience from 1/1/2000–12/
31/2012 using prospective database, during which time 937
cadaveric adult OLT were performed. Patient demographics,
recurrence, and survival were reviewed and Kaplan-Meier
plots generated with statistical comparison made using Log-
Rank test.
Results: 32% (300/937) patients had HCC. 243 (81%) of
HCC cases were diagnosed in the pre-transplant work-up and
210 underwent liver directed therapy prior to OLT. 45
(22.3%) of patients were outside of Milan before
downstaging (ALTSG stage III – 27; stage IVA1 – 13; Stage
IVA- 5). No patient beyond Milan who failed to downstage
underwent OLT. One-, 3-, and 5-year patient survival in 45
down-staged cases was 91%, 82.4%, 78.9%, comparable to
within-Milan TACE’d cases (92.9%, 80.8% and 69.3%).
One-, 3-, 5-year recurrence-free survival in 45 down-staged
cases was 86.5%, 80.4%, 72.6%, also comparable to within-
Milan (88.4%, 77.7% and 64.2%). Recurrence rates were
19/249 (7.6%) for within Milan and 3/45 (6.7%) initially
beyond Milan but downstaged.
Conclusion: Liver transplantation remains a highly effec-
tive therapy for patients with HCC, with excellent long-term
survival and low recurrence risk. Patients beyond Milan
should be required to undergo tumor downstaging with a
period of observation prior to undergoing OLT.
LO-C.09 IS LIVER TRANSPLANTATION
SAFE AND EFFECTIVE FOR GERIATRIC
(>70 YEARS) RECIPIENTS? A CASE
CONTROLLED ANALYSIS
G. C. Wilson, R. C. Quillin, K. Wima, J. M. Sutton,
D. J. Hanseman, I. M. Paquette, F. Paterno, E. S. Woodle,
D. E. Abbott and S. A. Shah
University Of Cincinnati Department Of Surgery,
Cincinnati, OH
Introduction: As the US population continues to age,
patients aged ≥70 years are being evaluated for liver trans-
plantation (LT) with increasing frequency but their outcomes
after LT are unknown.
Methods: Using a novel linkage of the University
HealthSystem Consortium (UHC) and Scientific Registry of
Transplant Recipients (SRTR) databases, we identified
13,819 patients who underwent LT from 2007–2012. Patients
were sorted into two cohorts: recipient aged ≥70 years at LT
(n = 318) vs. recipients <70 years (n = 12,073). A 2 : 1 case
control analysis was performed with matched cohorts based
on propensity scores.
Results: Older recipients had lower MELD scores at LT
(median 15 vs. 19, p < 0.0001), were transplanted at high
volume centers more (47.3% vs. 34.4%, p < 0.0001) and
received more grafts from donors aged >60 years (24.2% vs.
15.5%, p < 0.0001), but had similar donor race, cause of
donor death, DRI, and cold ischemia time (p > 0.05 for
each). The two cohorts had similar hospital length of stay, in
hospital mortality, hospital cost, and 30-day readmission
rates. Graft survival was similar between the two cohorts
(p = 0.09) but recipients ≥70 years had worse overall long-
term survival (p = 0.008; Figure 1). A case controlled analy-
sis confirmed that although hospital LOS was longer in the
older cohort, short-term results were similar between the two
groups.
Conclusions: Selected geriatric recipients have similar
perioperative outcomes and graft survival compared to
younger recipients; however, they have worse overall sur-
vival following LT suggesting that medical care and health
maintenance may be important in long-term patient survival.
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LO-C.10 RECIPIENT OBESITY
ADVERSELY AFFECTS LONG-TERM
GRAFT AND OVERALL SURVIVAL IN A
SINGLE INSTITUTION ANALYSIS
K. D. Conzen1, N. Vachharajani1, K. M. Collins1,
C. D. Anderson2, Y. Lin1, J. R. Wellen1, S. Shenoy1,
J. A. Lowell1, M. Doyle1 and W. Chapman1
1Washington University In St. Louis, Department Of
Surgery, St. Louis, MO; 2University Of Mississippi Medical
Center, Department Of Surgery, Jackson, MS
Introduction: The effect of obesity in liver transplantation
remains controversial. Earlier data from our institution dem-
onstrated no significant difference in post-operative compli-
cations or one-year mortality. We hypothesized that obesity
alone has minimal effect on long-term graft and overall
survival.
Methods: A retrospective study of all primary orthotopic
liver transplants (OLT) at our center (1/1/2002–12/31/2012)
was conducted. OLT recipients were divided into six groups
based on pre-transplant BMI: Group 1 (BMI < 18), Group 2
(18–24.9), Group 3 (25–29.9), Group 4 (30–35), Group 5
(35.1–40) and Group 6 (>40). Pre- and post-transplant
parameters were compared between groups. Differences in
outcomes were determined using the log-rank test, Chi-
square test, and student’s t-test; p-value < 0.05 was consid-
ered significant.
Results: Seven hundred eighty-five patients met inclusion
criteria. Numbers of recipients in each group were: (group
1)9, (2)210, (3)294, (4)169, (5)77, (6)26. No differences
were observed in race, age, massive ascites, or diabetes.
Recipients with BMI >35 were more likely to have NASH
cirrhosis (p < 0.0001) and wait longer for transplant
(p = 0.002). There were no differences in operative time, ICU
LOS, hospital LOS, vascular thrombosis, bleeding, biliary
complications, or infection. Seven year graft survival (36.7%
vs 62–79%) and overall survival (38% vs 62–81%) were
significantly decreased for BMI >40 (p < .02).
Conclusion: Obesity increasingly impacts the field of liver
transplantation. Although limited by a single institution, our
data suggests that morbid obesity adversely affects long-term
outcomes despite similar short-term results. Further analysis
is indicated to identify risk factors for poor outcomes in
morbidly obese patients.
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OP-I.01 HIDA SCAN OF THE FLR IS
SUPERIOR TO VOLUMETRY TO ASSESS
LIVER FUNCTION IN ALPPS
E. Schadde1, M. Lesurtel1, N. Schäfer2 and P. Clavien1
1Dept. Of Visceral And Transplant Surgery, University Of
Zurich Hospital, Zurich, ZURICH; 2Dept. Of Nuclear
Medicine, University Of Zurich Hospital, Zurich, ZURICH
Introduction: ALPPS (Associating Liver Partition with
Portal vein ligation for Staged hepatecomy) induces rapid
hypertrophy, but the functionality of the tissue has been
questioned even when volume cut-offs of the future liver
remnants of 30% prior to resection are respected. 99m-
Technetium-mebrofenin clearance capacity of the future liver
remnant (FLR) of less than 1.8 %/min/BSA using HIDA
scintigraphy has been postulated to increase the risk of post-
operative liver failure after resection. We assessed the value
of HIDA in a pilot series of patients undergoing ALPPS and
Portal Vein Embolization (PVE).
Methods: Four patients undergoing ALPPS were compared
with 4 patients undergoing PVE before stage 1 and stage 2.
Scintigraphy was performed by intraveneous injection
80 MBq99m Technetium-mebrofenin. Dual head dynamic
acquisitions were used to calculate FLR function. MRI
volumetry was used to assess volume changes. Postoperative
liver failure was assessed using 50/50 criteria.
Results: One patient in the ALPPS group and one patient in
the PVE group developed fatal postoperative liver failure.
These two patients had a FLR function after hypertrophy of
only 2.14 (ALLPS) and 1.28 (PVE) %/min/BSA, despite
having reached a FLR volume of greater than 30%. In con-
trast the FLR function of patients with an uncomplicated
postoperative course was 3.6, 5.5 and 4.6 %/min/BSA in the
ALPPS group and 2.3, 3.7 and 5.4 %/min/BSA in the PVE
group.
Conclusion: In ALPPS and also PVE, assessment of FLR
function using 99m Technetium-mebrofenin clearance capac-
ity of the future liver remnant is superior to volumetry to
assess resectibility.
OP-I.02 MORBIDITY AND MORTALITY
IN 1174 PATIENTS UNDERGOING
HEPATIC PARENCHYMAL
TRANSECTION USING A STAPLER
DEVICE
M. Raoof2, T. A. Aloia1, J. Vauthey1 and S. A. Curley1
1University Of Texas, MD Anderson Cancer Center,
Houston, TX; 2University Of Arizona, Tucson, AZ
Background: Transection of liver parenchyma using sta-
plers is now commonly performed. Large studies are needed
to assess the usefulness of the technique as well as peri-
operative outcomes.
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